Dermata Therapeutics Inc.

0.02
0.00 (31.58%)
At close: Apr 04, 2025, 10:26 AM
31.58%
Bid 0.01
Market Cap 82K
Revenue (ttm) n/a
Net Income (ttm) n/a
EPS (ttm) -2.156
PE Ratio (ttm) -0.01
Forward PE n/a
Analyst n/a
Ask 0.02
Volume 2,682
Avg. Volume (20D) 13,661.924
Open 0.01
Previous Close 0.02
Day's Range 0.01 - 0.02
52-Week Range 0.02 - 0.02
Beta 0.58

About DRMAW

Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, a once-weekly topical product that is under clinical development for the treatment of acne vulgaris, psoriasis vulgaris, and papulopustular rosacea. It is also developing DMT410 for the treatment of hyperhidrosis and aesthetic conditions. The company was founded in 2...

Industry Biotechnology
Sector Healthcare
IPO Date Aug 13, 2021
Employees 8
Stock Exchange NASDAQ
Ticker Symbol DRMAW
Full Company Profile
No News article available yet